Merola J, Sofen H, Thaci D, Paul C, Imafuku S, Banerjee S, Armstrong A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2021 Nov. 5 [cited 2024 Jul. 3];5(6):s36. Available from: https://jofskin.org/33014/index.php/skin/article/view/1387